CAJ | 학술논문

目的：评价同步整合加量调强放射治疗（SIB-IMRT）技术治疗原发性食管癌的近期疗效及不良反应。方法32例原发性食管癌患者均采用5野或7野的 SIB-IMRT 技术进行放射治疗。肿瘤靶区（GTV）220 cGy／F，总剂量6600 cGy／30F；临床靶区（CTV）单次剂量180 cGy，总剂量5400 cGy／30F。结果32例原发性食管癌患者均按计划完成放射治疗。放射治疗结束时有26例患者食管病灶完全缓解，完全缓解率为81％（26／32）；4例部分缓解，部分缓解率为13％。右肺 V20为9％～21％，左肺 V20为11％～23％。其中Ⅰ～Ⅱ级放射性食管炎共11例，发生率为34％。Ⅰ～Ⅱ级放射性气管炎6例，发生率为19％，无Ⅲ级以上急性不良反应发生。结论SIB-IMRT 技术治疗原发性食管癌疗效好，不良反应可耐受。
목적：평개동보정합가량조강방사치료（SIB-IMRT）기술치료원발성식관암적근기료효급불량반응。방법32례원발성식관암환자균채용5야혹7야적 SIB-IMRT 기술진행방사치료。종류파구（GTV）220 cGy／F，총제량6600 cGy／30F；림상파구（CTV）단차제량180 cGy，총제량5400 cGy／30F。결과32례원발성식관암환자균안계화완성방사치료。방사치료결속시유26례환자식관병조완전완해，완전완해솔위81％（26／32）；4례부분완해，부분완해솔위13％。우폐 V20위9％～21％，좌폐 V20위11％～23％。기중Ⅰ～Ⅱ급방사성식관염공11례，발생솔위34％。Ⅰ～Ⅱ급방사성기관염6례，발생솔위19％，무Ⅲ급이상급성불량반응발생。결론SIB-IMRT 기술치료원발성식관암료효호，불량반응가내수。
Objective To evaluate the short-term efficacy and adverse events of simultaneous inte-grated boost intensity-modulated radiation therapy (SIB-IMRT)in the treatment of primary esophageal cancer. Methods Thirty-two patients diagnosed with primary esophageal cancer were treated with 5-or 7-field SIB-IM-RT.Gross target volume (GTV)was given at a dose of 220 cGy/F with a total dose of 6 600 cGy/30F.Clini-cal target volume (CTV)was given at a single dose of 180 cGy/F with a total dose of 5 400 cGy/30F.Results All 32 patients successfully completed the chemotherapy.The complete response rate was 81% (26 /32)and partial response rate was 13% (4 /32).The V20 of the left lung ranged from 11% to 23% and 9%-21% for the V20 of the right lung.Eleven patients (34%)presented with grade Ⅰ-Ⅱ radiation esophagitis and 6 (19%)had grade Ⅰ-Ⅱ radiation tracheitis.Conclusions SIB-IMRT is an effective therapy in treating pri-mary esophageal cancer and the adverse events are tolerable.